Live Q&A: Can Novo Win Back Investors in Fierce Obesity Race?

Novo once led the obesity drug market — now it's down more than 60% in the past year. With investors putting pressure on the Danish company, can it turn things around? Bloomberg’s Rachel Evans speaks with reporters Madison Muller, Naomi Kresge and Sanne Wass in a Live Q&A on Friday, February 27 at 8 a.m. ET. While anyone can listen, Bloomberg digital subscribers and Terminal clients have the exclusive opportunity to ask our team questions to answer in real-time. This conversation will be recorded and made available.